Disclosure of payments made to HCPs and HCOs in the UK

Disclosure of payments made to HCPs and HCOs in the UK

ALK-Abelló Ltd is committed to greater transparency of financial relationships with healthcare professionals and healthcare organisations. Alongside other ABPI member companies, from 2015 we are disclosing all transfers of value made to individually named healthcare professionals and healthcare organisations. This is in line with the ABPI Code of Practice as well as the EFPIA Disclosure Code, which has been adopted across 33 European countries. This disclosure is made annually on the ABPI website, Disclosure UK.

Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020

As part of the pharmaceutical industry’s annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies’ disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.) Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, ALK-Abelló Ltd’s 2019 transfer of value data has been published on Disclosure UK in aggregate.

Commitment to Transparency

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

In the interim, where ALK Abelló Ltd has obtained consent to do so, details of our 2019 Transfers of Value are available by following this link. Any healthcare professional or organisation who wishes to withdraw their consent to disclose transfers of value in detail may do so by emailing UKHUDisclosure@alk-abello.com. These amounts will then be included in our aggregate disclosure.

Our payments made to HCPs and HCOs in the UK in 2019

In 2019 ALK-Abelló Ltd paid a total of £27,714.10 to support 55 UK HCP’s to attend scientific conferences and meetings, to speak at ALK-Abelló meetings and to provide various consultancy services. Disclosure at an individual level is voluntary. Where consent has not been obtained to disclose on a named basis the total amount is shown in aggregate.

In addition to the transfers of value stated above, £24,349.50 was paid to HCPs and HCOs for costs directly associated with research and development.

ALK-Abelló Ltd also paid a total of £56,910 to HCO’s in sponsorships and grants, details of individual payments to HCO’s can be also be found in the link above.

Payments made to patient organisations and charities are not required to be disclosed as part of the ABPI disclosure process and are therefore listed below:

Financial Support Given to Patient Organisations and Charities

In 2010 ALK UK Ltd gave financial support to the following patient organisations & charities:

Anaphylaxis Campaign £27,890

Educational support to help raise awareness of the signs, symptoms and treatment options for patients at risk of anaphylaxis.

Allergy UK £5,000

Educational support to help raise awareness of the signs, symptoms and treatment options for patients at risk of anaphylaxis.

Last updated: 2020.06.29